Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status

The Potential of Senescence as a Target for Developing Anticancer Therapy

“…The elimination of senescent lymphoma occurs through caspase-12- and caspase-3-mediated endoplasmic-reticulum-related apoptosis [ 164 ]. Nano-drugs, such as lapatinib- poly(amidoamine) and fulvestrant- poly(amidoamine), promoted the elimination of doxorubicin-induced senescent breast cancer cells by apoptosis-mediated senolysis [ 84 ]. Thus, the induction of senescence can sensitize cancer cells to senolytic drugs.…”

“…Senescent cells display resistance to apoptosis owing to high level of BCL-2 [ 83 ], suggesting the role of senescence in therapeutic resistance. Lapatinib and fulvestrant (EGFR and HER2 inhibitors) treatment induced apoptosis in chemotherapy-induced senescent breast cancer cells [ 84 ]. Senescence induced by radiation, oncogenes, and chemicals increased the expression of BCL-2 in non-transformed retinal pigment endothelial cells and fibroblasts [ 83 ].…”

Platelet membrane-based biochemotactic-targeting nanoplatform combining PDT with EGFR inhibition therapy for the treatment of breast cancer

“…[31][32][33] The chemotherapy drug lapatinib (Lap), which is approved by the U.S. Food and Drug Administration (FDA) for clinical breast cancer tumor treatment, acts on EGFR and human epidermal receptor 2 (HER-2) to effectively block tumor new angiogenesis and tumor cell growth signals, ultimately inhibiting tumor migration and invasion. 34,35 Therefore, it can be predicted that the combined use of Lap during PDT can not only clear the solid tumor in situ, but also inhibit the growth, recurrence and metastasis of residual tumors. Accordingly, as described above, herein, we constructed a novel intelligent biomimetic nanoparticle with biochemotactic-targeting ability for the treatment of breast cancer in combination with photodynamic therapy and EGFR inhibition therapy.…”

Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy

“…The factors IL-6 and IL-8 secreted by senescent cells promote angiogenesis and tumor vascularization, promoting BRCA tumor cell invasion [ 16 ]. Lapatinib (L) and Fulvestrant (F), the classic drugs for targeted anti-BRCA therapy, were found to induce cell senescence in BRCA [ 17 ]. Senescence is characterized by heterogeneity, which is becoming a key factor in drug resistance in triple-negative breast cancer treatment [ 18 ].…”